R. Castro-Santamaria

发表

Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2014, Cancer.

Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2015, Cancer Prevention Research.

Prostate cancer detection using quantitative T2 and T2‐weighted imaging: The effects of 5‐alpha‐reductase inhibitors in men on active surveillance

Brandon Whitcher, F. Giganti, C. Moore, 2018, Journal of magnetic resonance imaging : JMRI.

Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE

C. Roehrborn, S. Freedland, D. Moreira, 2017, The Journal of urology.

Metabolic syndrome‐like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study

G. Andriole, S. Freedland, D. Moreira, 2015, BJU international.

Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2015, The Journal of urology.

Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2014, Clinical Cancer Research.

Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

H. Cohen, D. Bostwick, G. Andriole, 2015, The Journal of urology.

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens

G. Andriole, S. Freedland, D. Moreira, 2018, Scandinavian journal of urology.

Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations

C. Roehrborn, G. Andriole, S. Freedland, 2017, World Journal of Urology.

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD

E. Kerwin, E. Bateman, C. Crim, 2019, International journal of chronic obstructive pulmonary disease.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

G. Andriole, S. Freedland, D. Moreira, 2012, European urology.

Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study

G. Andriole, S. Freedland, D. Moreira, 2017, International journal of urology : official journal of the Japanese Urological Association.

Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2015, The Prostate.

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD

C. Crim, R. Castro-Santamaria, M. Watkins, 2020, BMC Pulmonary Medicine.

Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain

S. Freedland, D. Moreira, R. Castro-Santamaria, 2017, The Journal of urology.

Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.

C. Roehrborn, S. Freedland, D. Moreira, 2016, The Journal of urology.

Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.

C. Roehrborn, S. Freedland, D. Moreira, 2016, European urology.

Platinum Priority – Benign Prostatic Hyperplasia

C. Roehrborn, S. Freedland, D. Moreira, 2016 .

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study

C. Roehrborn, G. Andriole, S. Freedland, 2018, Prostate Cancer and Prostatic Diseases.

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy

G. Andriole, S. Freedland, D. Moreira, 2018, BJU international.

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2015, Cancer Prevention Research.

Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial

G. Andriole, S. Freedland, D. Moreira, 2017, Cancer Prevention Research.

Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE

C. Roehrborn, G. Andriole, S. Freedland, 2018, The Journal of urology.

Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial

G. Andriole, S. Freedland, D. Moreira, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2016, Prostate Cancer and Prostatic Diseases.

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

Jianfeng Xu, G. Andriole, W. Isaacs, 2012, Journal of internal medicine.

Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study

Daniel Moreira, Leah Gerber, G. Andriole, 2014, Clinical Cancer Research.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study

C. Roehrborn, G. Andriole, S. Freedland, 2018, Prostate Cancer and Prostatic Diseases.

Baseline Subject Characteristics Predictive of Compliance with Study-Mandated Prostate Biopsy in Men at Risk of Prostate Cancer: Results from REDUCE

G. Andriole, S. Freedland, D. Moreira, 2015, Prostate Cancer and Prostatic Diseases.

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

1176 SMOKING IS ASSOCIATED WITH ACUTE PROSTATIC INFLAMMATION IN MEN WITH A NEGATIVE PROSTATE BIOPSY: RESULTS FROM THE REDUCE STUDY

G. Andriole, S. Freedland, D. Moreira, 2013 .

Racial differences in prostate inflammation: results from the REDUCE study

G. Andriole, C. Drake, S. Freedland, 2016, Oncotarget.

EXTENT OF BASELINE PROSTATE ATROPHY IS ASSOCIATED WITH LOWER INCIDENCE OF LOW‐ AND HIGH‐GRADE PROSTATE CANCER ON REPEAT BIOPSY: MP20‐06

G. Andriole, S. Freedland, D. Moreira, 2017, Urology.

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2016, The Journal of urology.

Racial differences in prostate inflammation: results from the REDUCE study

G. Andriole, C. Drake, S. Freedland, 2016, Oncotarget.

Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.

S. Freedland, R. Castro-Santamaria, J. Nickel, 2016, The Journal of urology.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

G. Andriole, S. Freedland, D. Moreira, 2012, European urology.